Neurocrine Biosciences Adds New Director
Ticker: NBIX · Form: 8-K · Filed: Apr 4, 2025 · CIK: 914475
| Field | Detail |
|---|---|
| Company | Neurocrine Biosciences Inc (NBIX) |
| Form Type | 8-K |
| Filed Date | Apr 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, governance
Related Tickers: NBIX
TL;DR
NBI adds Dr. David L. M.D. to board, effective April 2, 2025.
AI Summary
Neurocrine Biosciences, Inc. announced on April 2, 2025, the election of Dr. David L. M. M.D. to its Board of Directors. Dr. M.D. will serve as a Class II director until the 2027 annual meeting of stockholders. He brings extensive experience in neurology and pharmaceutical development to the company.
Why It Matters
The addition of a new director with specialized experience can bring fresh perspectives and expertise to the company's strategic decision-making and oversight.
Risk Assessment
Risk Level: low — This filing pertains to a routine board appointment and does not involve significant financial or operational changes.
Key Players & Entities
- Neurocrine Biosciences, Inc. (company) — Registrant
- Dr. David L. M.D. (person) — Newly elected director
- April 2, 2025 (date) — Effective date of election
FAQ
Who is the new director elected to the Neurocrine Biosciences Board?
Dr. David L. M.D. was elected to the Board of Directors.
What is the term of Dr. David L. M.D.'s directorship?
Dr. M.D. will serve as a Class II director until the 2027 annual meeting of stockholders.
When was the election of the new director effective?
The election was effective as of April 2, 2025.
What is the primary area of expertise for the new director?
Dr. M.D. brings extensive experience in neurology and pharmaceutical development.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 4, 2025 by Dr. David L. M.D. regarding NEUROCRINE BIOSCIENCES INC (NBIX).